Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- GENERICS NEWS IN BRIEF
September 22, 2008
- NovoRapid 30 Mix Decreases HbA1c without Increasing Incidence of Serious Hypoglycemic Events
September 22, 2008
- BUSINESS NEWS IN BRIEF
September 22, 2008
- Saxagliptin Effective in Combination with Other Oral Antidiabetic Agents
September 22, 2008
- Japanese Pharma Industry Group Visits UCB
September 22, 2008
- RAD001 Granted Priority Review Status in the US
September 22, 2008
- Meiji Seika, Meiji Dairy to Integrate Businesses
September 22, 2008
- Will Distribution Practices Be Improved? Part 2
September 22, 2008
- NovoRapid 30 Mix Has Turned Out to Be Global Blockbuster: Novo Nordisk Pharma
September 22, 2008
- Loxonin Tape Leads Rep Track Survey Ranking in July
September 15, 2008
- AIDS Drugs Effective against Resistant Virus Needed
September 15, 2008
- Yamato Will Not Be Able to Be Profitable with Generics Alone: Mr Kumakura
September 15, 2008
- Publicity on Effective Migraine Treatment Needed: GSK Seminar
September 15, 2008
- Will Distribution Practices Be Improved? Part 1
September 15, 2008
- Next Generation of Antidiabetic Drugs Discussed: Tokyo Seminar
September 15, 2008
- Suzuken Expects Price Settlement Rate of Over 70% at the End of September
September 15, 2008
- No Subjective Symptoms in 27% of Glaucoma Patients with Impairment of Half of Visual Field
September 15, 2008
- World's 1st Drug for Idiopathic Pulmonary Fibrosis Recommended for Approval
September 15, 2008
- Shionogi to Enter US Market by Acquiring Sciele
September 15, 2008
- DSP to Design Independent US Marketing System by Mid-2009
September 15, 2008
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…